local_hospital

Spaarne Gasthuis

Address
lock Available on a paid plan

Hematologic Malignancies and Lymphoma

At Spaarne Gasthuis, clinical research in hematology focuses on aggressive and relapsed blood cancers, with studies designed to improve survival, deepen remission, and reduce treatment-related harm.

  • Trials in diffuse large B-cell lymphoma, mantle cell lymphoma, and other non-Hodgkin lymphomas
  • Research in multiple myeloma, chronic lymphocytic leukemia, myelofibrosis, and polycythemia vera
  • Testing new combinations and maintenance strategies to improve response and extend disease control
  • Studies aimed at lowering cardiac toxicity and other side effects of standard cancer treatment

These projects reflect a strong interest in refining blood cancer care while making treatment more effective and better tolerated.

Solid Tumors and Gastrointestinal Cancer

The site has a broad portfolio in oncology for colorectal cancer, gastric cancer, esophageal cancer, rectal cancer, and advanced solid tumors, with a clear emphasis on improving outcomes in both early and metastatic disease.

  • Studies in colon cancer, rectal cancer, and colorectal liver metastases
  • Research in gastric and esophagogastric cancer
  • Trials exploring organ-preserving treatment, neoadjuvant approaches, and better recurrence prevention
  • Work evaluating whether treatment intensification or de-escalation can maintain control while reducing toxicity

These trials are aimed at finding more personalized ways to treat gastrointestinal malignancies and preserve quality of life.

Breast Cancer and Hormone-Driven Disease

Research in breast cancer at Spaarne Gasthuis spans early-stage, metastatic, and hormone receptor-positive disease, with studies focused on recurrence prevention and treatment sequencing.

  • ER-positive, HER2-negative early breast cancer
  • HER2-positive breast cancer and triple-negative breast cancer
  • Metastatic breast cancer trials evaluating endocrine therapy, targeted therapy, and immunotherapy combinations
  • Studies addressing symptoms linked to hormone therapy, including vasomotor symptoms

This work aims to improve long-term disease control while making treatment easier to tolerate for people living with breast cancer.

Genitourinary Cancers

The clinical trial program includes substantial work in prostate cancer and bladder cancer, especially in settings where new treatment strategies may improve survival or reduce the burden of therapy.

  • Metastatic castration-resistant prostate cancer and low-volume metastatic castration-sensitive prostate cancer
  • Muscle-invasive bladder cancer and high-risk non-muscle-invasive bladder cancer
  • Studies testing new hormonal, immune-based, and bladder-sparing approaches
  • Research looking at whether treatment can be safely shortened, switched, or personalized

These trials support more tailored care for urothelial and prostate malignancies, with attention to both effectiveness and side effects.

Cardiovascular, Metabolic, and Kidney Disease

Beyond cancer, the site also contributes to studies in cardiovascular disease, obesity, diabetes, and chronic kidney disease, reflecting an interest in preventing major complications and improving long-term health.

  • Acute myocardial infarction, atrial fibrillation, and broader atherosclerotic cardiovascular disease
  • Heart failure, stroke, and venous thromboembolism
  • Type 2 diabetes mellitus, obesity, and elevated lipoprotein(a)
  • Kidney failure and advanced chronic kidney disease

These trials are designed to test new ways to prevent serious events and improve outcomes in common cardiometabolic conditions.

Neurology, Immunology, and Inflammatory Disease

Clinical research here also extends to neurologic and immune-mediated diseases, with studies exploring better disease control, improved diagnosis, and more individualized treatment.

  • Multiple sclerosis and mild cognitive impairment or dementia
  • Plaque psoriasis and other inflammatory skin disease
  • Immune system diseases and treatment personalization strategies
  • Research focused on matching therapy intensity to patient needs and reducing unnecessary exposure

This area shows an emphasis on better long-term management of chronic inflammatory and neurologic disorders.

Diagnostics, Supportive Care, and Women’s Health

The trial portfolio at Spaarne Gasthuis also includes studies that improve diagnosis, symptom control, and reproductive health, showing a wider commitment to patient-centered care.

  • Diagnostic research such as tau PET for better clinical assessment
  • Supportive care studies in advanced cancer, including constipation prevention and symptom relief
  • Infertility, unexplained subfertility, and preterm birth prevention
  • Trials in pneumonia, influenza, and sepsis to improve acute care outcomes

These projects aim to make care more precise, reduce complications, and improve everyday well-being across a range of medical specialties.

Site Overview

assignment
94
connected trials
corporate_fare
35
sponsors
science
247
IMPs

Activity Indicator

Last 6 months

10
Trials started
-9% vs previous period.
11
Trials started 6–12 months ago
94
Total trials linked
Highly Active
trending_downDeclining-9%
2
3
2
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 18 therapeutic areas and 15 of 247 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 236 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
51
Sponsors (total)
35
Active sponsors
25

Sponsor Network

Top 25 by active trials.

lock +24 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +20 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
94
Outperforms 90% of sites
public
Therapeutic diversity
18areas
Outperforms 87% of sites
groups
Sponsor diversity
35sponsors
Outperforms 87% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Spaarne Gasthuis

lock Showing 1 of 94 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studiesBayer Consumer Care AGPhase IIINot RecruitingOct 2020

IMP list

lock Showing 1 of 247 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Capecitabine8Unknown2017-06-162026-07-08

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.